利培酮联合达营片对精神分裂症血浆神经递质的影响

Effects of Daying tablet add-on risperidone on plasma neurotransmitter of schizophrenia

目的 探讨利培酮联合达营片对精神分裂症患者血浆神经递质的影响及与相关性分析。 方法 应用随机、双盲、对照研究，将67例符合ICD-10诊断标准的精神分裂症患者随机分为研究组30例， 对照组37例，分别予以利培酮合并达营片和利培酮合并安慰剂治疗，疗程12周。测定两组治疗前后血浆 神经递质多巴胺（DA）、5-羟色胺（5-HT）和5-羟吲哚乙酸（5-HIAA）的浓度，并采用PANSS量表评定疗效。 结果 治疗后研究组DA、5-HIAA 降低，而5-HT水平增加；对照组DA、5-HT和5-HIAA都增加；两组治 疗前后差值比较差异无统计学意义（P ＞ 0.05）。且两组DA、5-HT和5-HIAA含量变化与疗效无相关性 （P＞ 0.05）。结论 经治疗12周后，两组在DA、5-HT和5-HIAA这3个神经递质的变化未发现明显差异， 且与疗效之间不存在相关性。

the treatment of schizophrenia and its correlation analysis. Methods A randomized doubleblind controlled study was applied. A total of 67 patients meeting the criteria of ICD-10 for schizophrenia were randomly divided into the Daying tablet group（ n=30） and the placebo group（ n=37）. The participants were treated with Daying tablet add-on risperidone and Daying combined placebo tablet respectively for 12 weeks. The level of dopamine（DA）, 5-hydroxytryptamine（ 5-HT） and 5-hydroxyindoleacetic acid（ 5-HIAA） were measured before and after treatment, at the same time the Positive and Negative Syndrome Scale（ PANSS） was applied to evaluate curative effect. Results After treatment, plasma levels of DA and 5HIAA decreased, and 5-HT increased in the Daying tablet group, while all the measured neurotransmitters of the placebo group decreased. There was no significant difference between the two groups after the treatment（ P〉0.05）. In addition, there was no significant correlation between changes of measured neurotransmitter concentration and the curative effect. Conclusions The changes of plasma neurotransmitters（ including DA, 5-HT and 5-HIAA） have no significant difference between the Daying combined with risperidone group and the placebo group in schizophrenia patients, and there is no significant correlation with efficacy.